An Introduction to Markov Modelling for Economic Evaluation
- 1 January 1998
- journal article
- review article
- Published by Springer Nature in PharmacoEconomics
- Vol. 13 (4), 397-409
- https://doi.org/10.2165/00019053-199813040-00003
Abstract
Markov models are often employed to represent stochastic processes, that is, random processes that evolve over time. In a healthcare context, Markov models are particularly suited to modelling chronic disease. In this article, we describe the use of Markov models for economic evaluation of healthcare interventions. The intuitive way in which Markov models can handle both costs and outcomes make them a powerful tool for economic evaluation modelling. The time component of Markov models can offer advantages of standard decision tree models, particularly with respect to discounting. This paper gives a comprehensive description of Markov modelling for economic evaluation, including a discussion of the assumptions on which the type of model is based, most notably the memoryless quality of Markov models often termed the ‘Markovian assumption’. A hypothetical example of a drug intervention to slow the progression of a chronic disease is employed to demonstrate the modelling technique and the possible methods of analysing Markov models are explored. Analysts should be aware of the limitations of Markov models, particularly the Markovian assumption, although the adept modeller will often find ways around this problem.Keywords
This publication has 24 references indexed in Scilit:
- Deciphering death: a commentary on Gompertz (1825) ‘On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies’Philosophical Transactions Of The Royal Society B-Biological Sciences, 2015
- Modelling in Ecomomic Evaluation: An Unavoidable Fact of LifeHealth Economics, 1997
- The Iterative Use of Economic Evaluation as Part of the Process of Health Technology AssessmentJournal of Health Services Research & Policy, 1997
- Using Economics to Prioritize Research: A Case Study of Randomized Trials for the Prevention of Hip Fractures Due to OsteoporosisJournal of Health Services Research & Policy, 1996
- Timing and Timeliness in Medical Care EvaluationPharmacoEconomics, 1996
- A Cost-Utility Analysis of Laser-Assisted Angioplasty for Peripheral Arterial OcclusionsInternational Journal of Technology Assessment in Health Care, 1996
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Cost Effectiveness of Thrombolytic Therapy with Tissue Plasminogen Activator as Compared with Streptokinase for Acute Myocardial InfarctionNew England Journal of Medicine, 1995
- Determining Transition ProbabilitiesMedical Decision Making, 1994
- Discounting and health benefits: Another PerspectiveHealth Economics, 1992